Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2014

01-07-2014 | Editorial

Letter regarding Zhu et al. entitled “Assessment of the association between XRCC1 Arg399Gln polymorphism and glioma susceptibility”

Authors: Jue-Yu Zhou, Rong Shi, Lei Jiang, Ye Zeng, Wen-Li Ma

Published in: Tumor Biology | Issue 7/2014

Login to get access

Excerpt

To the Editor, …
Literature
1.
2.
Jacobs DI, Bracken MB. Association between XRCC1 polymorphism 399 G- > A and glioma among caucasians: a systematic review and meta-analysis. BMC Med Genet. 2012;13:97.PubMedCentralCrossRefPubMed
3.
Jiang L, Fang X, Bao Y, Zhou JY, Shen XY, Ding MH, et al. Association between the XRCC1 polymorphisms and glioma risk: a meta-analysis of case-control studies. PLoS One. 2013;8:e55597.PubMedCentralCrossRefPubMed
4.
Sun JY, Zhang CY, Zhang ZJ, Dong YF, Zhang AL, Wang ZW, et al. Association between XRCC1 gene polymorphisms and risk of glioma development: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:4783–8.CrossRefPubMed
5.
Wei X, Chen D, Lv T. A functional polymorphism in XRCC1 is associated with glioma risk: evidence from a meta-analysis. Mol Biol Rep. 2013;40:567–72.CrossRefPubMed
6.
Zhang H, Liu H, Knauss JL. Associations between three XRCC1 polymorphisms and glioma risk: a meta-analysis. Tumour Biol. 2013;34:3003–13.CrossRefPubMed
7.
Blair A, Burg J, Foran J, Gibb H, Greenland S, Morris R, et al. Guidelines for application of meta-analysis in environmental epidemiology. Isli risk science institute. Regul Toxicol Pharmacol. 1995;22:189–97.CrossRefPubMed
8.
Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999;282:1752–9.CrossRefPubMed
9.
10.
McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, Ruder AM, Butler M, Rajaraman P, et al. Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev. 2009;18:1118–26.PubMedCentralCrossRefPubMed
11.
Rajaraman P, Hutchinson A, Wichner S, Black PM, Fine HA, Loeffler JS, et al. DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol. 2010;12:37–48.PubMedCentralCrossRefPubMed
12.
Liu Y, Scheurer ME, El-Zein R, Cao Y, Do KA, Gilbert M, et al. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev. 2009;18:204–14.PubMedCentralCrossRefPubMed
13.
Felini MJ, Olshan AF, Schroeder JC, North KE, Carozza SE, Kelsey KT, et al. DNA repair polymorphisms XRCC1 and MGMT and risk of adult gliomas. Neuroepidemiology. 2007;29:55–8.CrossRefPubMed
14.
Kiuru A, Lindholm C, Heinavaara S, Ilus T, Jokinen P, Haapasalo H, et al. XRCC1 and XRCC3 variants and risk of glioma and meningioma. J Neurooncol. 2008;88:135–42.CrossRefPubMed
15.
Liu J, Sun H, Huang L, Hu P, Dai X. Relationship between XRRC1 polymorphisms and adult gliomas. Mod Pre Med. 2011;38:3340–1.
16.
Yosunkaya E, Kucukyuruk B, Onaran I, Gurel CB, Uzan M, Kanigur-Sultuybek G. Glioma risk associates with polymorphisms of DNA repair genes, XRCC1 and PARP1. Br J Neurosurg. 2010;24:561–5.CrossRefPubMed
17.
Luo KQ, Mu SQ, Wu ZX, Shi YN, Peng JC. Polymorphisms in DNA repair genes and risk of glioma and meningioma. Asian Pac J Cancer Prev. 2013;14:449–52.CrossRefPubMed
18.
Xu G, Wang M, Xie W, Bai X: Three polymorphisms of DNA repair gene XRCC1 and the risk of glioma: a case-control study in northwest china. Tumour Biol 2014;35:1389–95.
Metadata
Title
Letter regarding Zhu et al. entitled “Assessment of the association between XRCC1 Arg399Gln polymorphism and glioma susceptibility”
Authors
Jue-Yu Zhou
Rong Shi
Lei Jiang
Ye Zeng
Wen-Li Ma
Publication date
01-07-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1931-z

Other articles of this Issue 7/2014

Tumor Biology 7/2014 Go to the issue

Research Article

Metastatic lymph node ratio can further stratify prognosis in rectal cancer patients treated with preoperative radiotherapy: a population-based analysis

Research Article

Serum Zta antibody of Epstein–Barr virus exerts potential function in the diagnosis of nasopharyngeal cancer

Research Article

Dietary chlorophyllin abrogates TGFβ signaling to modulate the hallmark capabilities of cancer in an animal model of forestomach carcinogenesis

Research Article

Genetic variation in the major mitotic checkpoint genes and risk of breast cancer: a multigenic study on cancer susceptibility

Research Article

Clinical significance of serum tenascin-c levels in epithelial ovarian cancer

Research Article

Clinical significance of serum tenascin-C levels in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits